Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Inventory-to-Revenue : 0.00 (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Merrimack Pharmaceuticals Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Merrimack Pharmaceuticals's Average Total Inventories for the quarter that ended in Dec. 2023 was $0.00 Mil. Merrimack Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was $0.00 Mil.

Merrimack Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 stayed the same from Sep. 2023 (0.00) to Sep. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.

Merrimack Pharmaceuticals Inventory-to-Revenue Historical Data

The historical data trend for Merrimack Pharmaceuticals's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Merrimack Pharmaceuticals Inventory-to-Revenue Chart

Merrimack Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

Get a 7-Day Free Trial

Merrimack Pharmaceuticals Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Merrimack Pharmaceuticals's Inventory-to-Revenue

For the Biotechnology subindustry, Merrimack Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merrimack Pharmaceuticals's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Merrimack Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Merrimack Pharmaceuticals's Inventory-to-Revenue falls into.

Merrimack Pharmaceuticals Inventory-to-Revenue Calculation

Merrimack Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=	N/A

Merrimack Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (Q: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Revenue (Q: Dec. 2023 )
=	( (0	+	0)	/	1 )	/	0
=	0					/	0
=

Merrimack Pharmaceuticals (NAS:MACK) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Merrimack Pharmaceuticals's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	0	/	0	*	365 / 4
	=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Merrimack Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	0	/	0
	=

Merrimack Pharmaceuticals Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Merrimack Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Merrimack Pharmaceuticals (Merrimack Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Merrimack Pharmaceuticals Inc (NAS:MACK) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

One Broadway, 14th Floor, Cambridge, MA, USA, 02142

Website

https://www.merrimack.com

Merrimack Pharmaceuticals Inc is a biotechnology company that discovers, develops, and commercializes innovative medicines that consist of novel therapeutics paired with diagnostics to treat cancer. The company's core approach to systems biology is to apply multidisciplinary capabilities to build functional and predictive computational models of biological systems, such as cell signaling networks. Merrimack also enters into third-party agreements to further process and commercialize its products.

Executives

Eric Andersen	director, other: See Remarks	1507 BERKELEY ST, SUITE 7, SANTA MONICA X1 90404
Gary L Crocker	director, officer: President	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Noah G. Levy	director, other: See Remarks	60 EAST 42ND ST, 9TH FLOOR, NEW YORK NY 10165
Ana Radeljevic	director	2430 BEACON STREET, UNIT 201, CHESTNUT HILL MA 02467
Ulrik B. Nielsen	director	MERRIMACK PHARMACEUTICALS, INC., ONE KENDALL SQUARE, SUITE B7201, CAMBRIDGE MA 02139
Russell T Ray	director	2525 DUPONT DR, IRVINE CA 92612
Newtyn Capital Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Ledo Capital, Llc	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Te Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Newtyn Partners, Lp	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
Western Standard Partners Qp, L.p.	other: See Remarks	5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Partners Lp	other: See Remarks	5900 WILSHIRE BLVD, SUITE 650, LOS ANGELES CA 90036
Western Standard Llc	other: See Remarks	5757 WILSHIRE BLVD, SUITE 636, LOS ANGELES CA 90036
Newtyn Management, Llc	other: See Remarks	60 EAST 42ND STREET, 9TH FLOOR, NEW YORK NY 10165
22nw Gp, Inc.	10 percent owner, other: See Explanation of Responses	1455 NW LEARY WAY, SUITE 400, SEATTLE WA 98107